Tiering, exclusions, preferred products, step therapy, and how access teams prepare the evidence packet.
Six FDA-approved biosimilars now compete with Herceptin (trastuzumab) in oncology. This reference-product dossier maps every approved product, payer formulary...
Ten FDA-approved biosimilars now compete with Humira (adalimumab). This reference-product dossier maps every approved product, interchangeability status, payer adoption,...
Mounjaro and Zepbound contain the same active ingredient, tirzepatide, but carry different FDA indications, different coverage pathways, and different payer rules. This...
Humira (adalimumab) was once the world's best-selling drug, but its access landscape has transformed. With ten biosimilars now FDA-approved and all three major PBMs...
Rinvoq (upadacitinib) and Humira (adalimumab) represent two fundamentally different approaches to treating rheumatoid arthritis, psoriatic arthritis, and other...
Skyrizi (risankizumab) and Stelara (ustekinumab) are both IL-23 pathway inhibitors used in plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis...
Rinvoq (upadacitinib) is a JAK1 inhibitor approved for nine immune-mediated indications including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis,...
Stelara (ustekinumab) is an IL-12/23 inhibitor approved for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. With nine biosimilars now...